02921-MOU: Transcriptome Profiling of Canine Familial Dermatomyositis Skin Lesions and Treatment with a JAK Inhibitor to Identify Novel Pathways Involved in Pathogenesis

Grant Status: Open

Grant Amount: $57,658
Frane Banovic, DVM, PhD; University of Georgia
April 1, 2021 - March 31, 2023

Sponsor(s): American Shetland Sheepdog Association, Collie Health Foundation

Breed(s): Shetland Sheepdog, Collie
Research Program Area: Dermatology and Allergic Disease
Donate to Support this Research Program Area

One Health: Yes

Abstract

Dermatomyositis (DMS) is a chronic inflammatory and autoimmune disorder affecting primarily skin and muscle in both humans and dogs. Familial canine DMS is mainly described in predisposed breeds, such as Collies and Shetland Sheepdogs, and is characterized by severe inflammatory lesions leading to skin scarring with disfiguration, increased morbidity and decreased quality of life. Full clinical remission of DMS skin lesions can be difficult to achieve, reflecting a poor understanding of the pathogenesis of skin lesions in this disease. The transcriptome (gene expression analysis) investigation of human DMS tissues has revolutionized the understanding of the molecular fingerprint of DMS, further defining pathogenic immune pathways and identifying disease-specific biomarkers. Recently, a novel mechanism-based treatment using Janus kinase (JAK) inhibitors has led to a significant clinical and molecular improvement in refractory cutaneous DMS in humans. Oclacitinib is a safe and well-tolerated JAK inhibitor that has been used for the treatment of allergic dermatitis in dogs; however, the therapeutic effect of oclacitinib on canine immune-mediated diseases, such as DMS, has not been investigated. The main objective of this study is to perform a large-scale molecular signature analysis of canine familial DMS. Investigators hypothesize that integrating deep sequencing-based transcriptome profiling with systems biology analysis will identify novel pathogenic pathways and inflammatory biomarkers as canine DMS disease drivers, with potential for the development of novel targeted therapeutics. Furthermore, they will evaluate the effect of oclacitinib, a novel veterinary JAK inhibitor, on the modulation of the cutaneous DMS clinical signs in dogs. These results may suggest that JAK inhibition has the potential to reverse canine DMS pathomechanisms, opening the door to a new era of targeted treatment for this debilitating inflammatory skin disease.

Funding for the research is provided through the collaborative efforts and generosity of the Collie Health Foundation and American Shetland Sheepdog Association. The AKC Canine Health Foundation supports the funding of this effort and will oversee grant administration and scientific progress.


Learn how you can participate in this research!

Publication(s)

None at this time.

Help Future Generations of Dogs

Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.

Learn How to Help

Connect With Us:
Get Canine Health News:
Please leave this field empty
American Kennel Club Canine Health Foundation, Inc

8051 Arco Corporate Dr.
Suite 300
Raleigh, NC 27617
(888)-682-9696

Tax ID# 13-3813813

   2020 GuideStar logo

© 2020 AKC Canine Health Foundation | Privacy Policy | Site Map

Site by Blackbaud, Inc.

Powered by Blackbaud
nonprofit software